Tags

Type your tag names separated by a space and hit enter

Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report.
Acta Neurochir (Wien). 2019 03; 161(3):589-592.AN

Abstract

Cyproterone acetate (CPA) is an antiandrogenic drug which has recently been recognized to promote the occurrence and growth of intracranial meningiomas. Nomegestrol acetate (NOMAC) is a widely used progestin-like drug that could be suggested as an alternative for patients taking CPA. We report a case of CPA-related meningioma for which relay from CPA to NOMAC led to further tumor growth and cessation of NOMAC-induced tumor shrinkage. We suggest NOMAC can have a similar effect than CPA on meningiomas. The use of NOMAC as replacement for CPA in the presence of a meningioma should be discouraged until further evidence becomes available on the role of NOMAC in such instances.

Authors+Show Affiliations

Department of Neurosurgery, Hôpital Lariboisière, Paris VII-Diderot University, 2 rue Ambroise Pare, 75475, Paris, France. pierreolivier.champagne@aphp.fr. Department of Neurosurgery, Lariboisière Hospital, University of Paris Diderot, 2 rue Ambroise Paré, 75010, Paris, France. pierreolivier.champagne@aphp.fr.Department of Neurosurgery, Hôpital Lariboisière, Paris VII-Diderot University, 2 rue Ambroise Pare, 75475, Paris, France.Department of Neurosurgery, Hôpital Lariboisière, Paris VII-Diderot University, 2 rue Ambroise Pare, 75475, Paris, France.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

30666456

Citation

Champagne, Pierre-Olivier, et al. "Combined Hormonal Influence of Cyproterone Acetate and Nomegestrol Acetate On Meningioma: a Case Report." Acta Neurochirurgica, vol. 161, no. 3, 2019, pp. 589-592.
Champagne PO, Passeri T, Froelich S. Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report. Acta Neurochir (Wien). 2019;161(3):589-592.
Champagne, P. O., Passeri, T., & Froelich, S. (2019). Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report. Acta Neurochirurgica, 161(3), 589-592. https://doi.org/10.1007/s00701-018-03782-4
Champagne PO, Passeri T, Froelich S. Combined Hormonal Influence of Cyproterone Acetate and Nomegestrol Acetate On Meningioma: a Case Report. Acta Neurochir (Wien). 2019;161(3):589-592. PubMed PMID: 30666456.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combined hormonal influence of cyproterone acetate and nomegestrol acetate on meningioma: a case report. AU - Champagne,Pierre-Olivier, AU - Passeri,Thibault, AU - Froelich,Sebastien, Y1 - 2019/01/22/ PY - 2018/11/07/received PY - 2018/12/18/accepted PY - 2019/1/23/pubmed PY - 2020/1/14/medline PY - 2019/1/23/entrez KW - Cyproterone acetate KW - Hormone therapy KW - Meningioma KW - Nomegestrol acetate SP - 589 EP - 592 JF - Acta neurochirurgica JO - Acta Neurochir (Wien) VL - 161 IS - 3 N2 - Cyproterone acetate (CPA) is an antiandrogenic drug which has recently been recognized to promote the occurrence and growth of intracranial meningiomas. Nomegestrol acetate (NOMAC) is a widely used progestin-like drug that could be suggested as an alternative for patients taking CPA. We report a case of CPA-related meningioma for which relay from CPA to NOMAC led to further tumor growth and cessation of NOMAC-induced tumor shrinkage. We suggest NOMAC can have a similar effect than CPA on meningiomas. The use of NOMAC as replacement for CPA in the presence of a meningioma should be discouraged until further evidence becomes available on the role of NOMAC in such instances. SN - 0942-0940 UR - https://www.unboundmedicine.com/medline/citation/30666456/Combined_hormonal_influence_of_cyproterone_acetate_and_nomegestrol_acetate_on_meningioma:_a_case_report_ L2 - https://dx.doi.org/10.1007/s00701-018-03782-4 DB - PRIME DP - Unbound Medicine ER -